Menu Back toSession-0803-Breakthrough-Therapies-in-Diabetes-Diseases

The 7th DIA China Annual Meeting


Session 0803 Breakthrough Therapies in Diabetes Diseases

Session Chair(s)

Yan  Gong

Yan Gong

  • Senior Global Clinical Program Lead, Corporate Division of Medicine
  • Boehringer-Ingelheim, Germany, China
Huaqiong  SHEN, MD, PhD

Huaqiong SHEN, MD, PhD

  • Chief Medical Officer
  • Jiangsu Hengrui Medicine Co., Ltd., China

Slides for diabetes session

Speaker(s)

Kezhou  Zhang

Diabetes Treatment - Insulin and GLP-1

Kezhou Zhang

  • Vice President, Clinical & Medical & Regulatory
  • Novo Nordisk (China) Pharmaceuticals Co. Ltd., China
ShuHua  SHANG

Recent advancement of drug development in diabetes - synthetic chemical entity

ShuHua SHANG

  • Clinical Research Director
  • sanofi, China
Yan  Gong

Yan Gong

  • Senior Global Clinical Program Lead, Corporate Division of Medicine
  • Boehringer-Ingelheim, Germany, China
Eric  Hua

Status Quo, Challenges and Opportunities for Domestic Companies in Diabetes Therapies

Eric Hua

  • Overseas Clinical Project Manager, Clinical Operations
  • Gan & Lee Pharmaceuticals, China
Chengyu  Guan

Pipeline in Diabetes – From the Industrial Perspective (EN&CN)

Chengyu Guan

  • Medical Director
  • Jiangsu Hengrui Medicine Co., Ltd, China, China

Contact us

For exhibition, advertising and hosting inquiry, please contact:
Jean XU: jxu@kellencompany.com, or Sofie Peeters: speeters@kellencompany.com
Tel: +86 10 5923 1096

For general inquiry, please contact DIA China office:
dia@diachina.org
Tel: +86 10 5704 2650